{"id":15870,"date":"2023-07-25T13:46:00","date_gmt":"2023-07-25T05:46:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15870"},"modified":"2024-12-09T11:47:52","modified_gmt":"2024-12-09T03:47:52","slug":"eli-lillys-mirikizumab-and-chia-tai-tianqings-lanifibranor-enter-breakthrough-therapy-review","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15870","title":{"rendered":"Eli Lilly&#8217;s Mirikizumab and Chia Tai Tianqing&#8217;s Lanifibranor Enter Breakthrough Therapy Review"},"content":{"rendered":"\n<p>US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have both entered into the breakthrough therapy review process, marking a significant step in advancing treatments for moderate to severe active Crohn&#8217;s disease (CD) and non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis, respectively.<\/p>\n\n\n\n<p><strong>Mirikizumab: Anti-IL-23 Monoclonal Antibody for Crohn&#8217;s Disease and Other Indications<\/strong><br>Mirikizumab, an anti-IL-23 p19 subunit monoclonal antibody (mAb), is under development to treat CD, ulcerative colitis (UC), and plaque psoriasis. It was first approved in Japan for use in UC in March this year. Despite the indication filing being rejected in the US one month later due to manufacturing concerns, it received positive opinions in the European Union with an approval recommendation.<\/p>\n\n\n\n<p><strong>Lanifibranor: PPAR Agonist for NASH and Liver Fibrosis<\/strong><br>Lanifibranor is a peroxisome proliferators-activated receptor (PPAR) agonist developed by Inventiva to treat NASH and non-alcoholic fatty liver disease (NAFLD). Chia Tai Tianqing secured a licensing deal with Inventiva in September 2022, granting them exclusive rights to develop, manufacture, and commercialize the drug in Greater China. The drug has previously obtained breakthrough therapy designation (BTD) and fast-track status in the US, highlighting its potential impact on the treatment of NASH.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,34,661,2658,199,76,911,767],"class_list":["post-15870","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-breakthrough-therapy","tag-chia-tai-tianqing-pharmaceutical","tag-cttq-pharma","tag-eli-lilly","tag-nash","tag-nyse-lly","tag-parp"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Mirikizumab and Chia Tai Tianqing&#039;s Lanifibranor Enter Breakthrough Therapy Review - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have both entered into the breakthrough therapy review process, marking a significant step in advancing treatments for moderate to severe active Crohn&#039;s disease (CD) and non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15870\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Mirikizumab and Chia Tai Tianqing&#039;s Lanifibranor Enter Breakthrough Therapy Review\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15870\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T05:46:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T03:47:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Mirikizumab and Chia Tai Tianqing&#8217;s Lanifibranor Enter Breakthrough Therapy Review\",\"datePublished\":\"2023-07-25T05:46:00+00:00\",\"dateModified\":\"2024-12-09T03:47:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Breakthrough therapy\",\"Chia Tai Tianqing Pharmaceutical\",\"CTTQ Pharma\",\"Eli Lilly\",\"NASH\",\"NYSE: LLY\",\"PARP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15870#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15870\",\"name\":\"Eli Lilly's Mirikizumab and Chia Tai Tianqing's Lanifibranor Enter Breakthrough Therapy Review - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-25T05:46:00+00:00\",\"dateModified\":\"2024-12-09T03:47:52+00:00\",\"description\":\"US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have both entered into the breakthrough therapy review process, marking a significant step in advancing treatments for moderate to severe active Crohn's disease (CD) and non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis, respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15870\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15870#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Mirikizumab and Chia Tai Tianqing&#8217;s Lanifibranor Enter Breakthrough Therapy Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Mirikizumab and Chia Tai Tianqing's Lanifibranor Enter Breakthrough Therapy Review - Insight, China&#039;s Pharmaceutical Industry","description":"US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have both entered into the breakthrough therapy review process, marking a significant step in advancing treatments for moderate to severe active Crohn's disease (CD) and non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15870","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Mirikizumab and Chia Tai Tianqing's Lanifibranor Enter Breakthrough Therapy Review","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15870","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-25T05:46:00+00:00","article_modified_time":"2024-12-09T03:47:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15870#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15870"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Mirikizumab and Chia Tai Tianqing&#8217;s Lanifibranor Enter Breakthrough Therapy Review","datePublished":"2023-07-25T05:46:00+00:00","dateModified":"2024-12-09T03:47:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15870"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Breakthrough therapy","Chia Tai Tianqing Pharmaceutical","CTTQ Pharma","Eli Lilly","NASH","NYSE: LLY","PARP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15870#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15870","url":"https:\/\/flcube.com\/?p=15870","name":"Eli Lilly's Mirikizumab and Chia Tai Tianqing's Lanifibranor Enter Breakthrough Therapy Review - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-25T05:46:00+00:00","dateModified":"2024-12-09T03:47:52+00:00","description":"US pharmaceutical major Eli Lilly\u2019s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing\u2019s lanifibranor have both entered into the breakthrough therapy review process, marking a significant step in advancing treatments for moderate to severe active Crohn's disease (CD) and non-cirrhotic non-alcoholic steatohepatitis (NASH) with liver fibrosis, respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15870#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15870"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15870#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Mirikizumab and Chia Tai Tianqing&#8217;s Lanifibranor Enter Breakthrough Therapy Review"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15870"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15870\/revisions"}],"predecessor-version":[{"id":15871,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15870\/revisions\/15871"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}